NCT02753413View on ClinicalTrials.gov

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

June 28, 2016

Study Completion Date

June 28, 2016

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV vaccine GSK3003891A

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

BIOLOGICAL

Boostrix

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Trial Locations (1)

2610

GSK Investigational Site, Wilrijk

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02753413 - Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women | Biotech Hunter | Biotech Hunter